The Journal of Clinical Endocrinology & Metabolism · 1951 · 20 citations · 12 references
Organ PhysiologyEngineeringRadiation PhysicsRadioactive IodineRadiation ExposurePathologyDistribution OfSurgeryAnatomyBeta RayRadiation MedicineIodine Deficiency DisordersSurgical PathologyRadiopharmaceutical TherapyBeta RaysRadiation OncologyCardiologyNuclear MedicineRadiation Medicine ImagingRadiologyRadiological SciencesRadiation TherapyMedicineRadionuclide TherapyHistopathologyRadiation EffectsThyroid DiseaseThyroid HormoneOncologyHuman Tissue
RADIOACTIVE iodine, I131, is receiving extensive trial in the diagnosis and treatment of thyrotoxicosis (1–11) and carcinoma of the thyroid (12–16) and has been proposed as an agent for the induction of myxedema in euthyroid cardiac patients with intractable angina pectoris and congestive heart failure (17–20). The biologic effects of radioactive iodine depend largely on the emission of beta rays; the interaction of gamma rays from the I131 within a particular organ contributes a relatively small per cent of the radiation effect at any one point (21), although total body radiation from gamma rays emitted by I131 in the thyroid may contribute additional radiation which at the present time is not accurately measurable. Since the range in tissue of the beta ray of I131 is only approximately 2 mm., the concentration of I131 within any organ determines in large measure the amount of radiation to that organ.
12